Lupin launches generic Tamiflu in the US

Tamiflu capsules had annual sales of about US $518 million in the US as per IQVIA MAT December 2017 data, Lupin said in a BSE filing.

Pharmaceutical firm Lupin on Monday said it has launched its generic Oseltamivir Phosphate capsules used for treatment of influenza in the US markets.

Employees work at the pharmaceutical plant of Lupin in Verna, in the western state of Goa, India. (REUTERS)

The company said in a BSE filing that it has launched its tablets after receiving the approval from the United States Food and Drug Administration (USFDA).

The capsules, in the strengths of 30 mg, 45 mg and 75 mg, are generic versions of Hoffman-La Roche Inc’s Tamiflu capsules in the same strengths, it added.

The product is “indicated for the treatment of acute, uncomplicated influenza A and B in patients two weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients one year and older”, Lupin said.

The capsules had annual sales of about US $518 million in the US as per IQVIA MAT December 2017 data, it added.

Lupin was trading 2.57% higher at Rs 842.00 at 2.40 pm on the Bombay Stock Exchange.